



## Clinical trial results:

### A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects with Mild to Moderate Ulcerative Colitis (UC)

#### Summary

EudraCT number	2020-005232-30
Trial protocol	HU EE DE CZ BG SK IT
Global end of trial date	03 September 2024

#### Results information

Result version number	v1 (current)
This version publication date	23 October 2025
First version publication date	23 October 2025

#### Trial information

##### Trial identification

Sponsor protocol code	AMUC-2023
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04857112
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Salix Pharmaceuticals
Sponsor organisation address	400 Somerset Corporate Boulevard, Bridgewater, United States, 08807
Public contact	Clinical Trial Manager, Salix Pharmaceuticals, Inc., alison.magnotti-nagel@bauschhealth.com
Scientific contact	Clinical Trial Manager, Salix Pharmaceuticals, Inc., alison.magnotti-nagel@bauschhealth.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 September 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	03 September 2024
Global end of trial reached?	Yes
Global end of trial date	03 September 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Assess the efficacy and safety of oral amiselimod (MT-1303) compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC).

Protection of trial subjects:

This study was conducted in compliance with the study protocol and in accordance with Good Clinical Practices (GCPs), as described in the International Conference on Harmonisation (ICH) Harmonized Tripartite Guidelines for GCP, the United States Code of Federal Regulations (CFR) dealing with clinical studies (21 CFR Parts 11, 50, 54, 56, and 312), the ethical principles in the Declaration of Helsinki, and applicable local regulations. Before undertaking any study-related procedures with patients, the purpose and nature of the study, as well as possible adverse effects, were explained to them in understandable terms, and written informed consent was obtained from each individual. Each informed consent form (ICF) was to be appropriately signed and dated by the patient and the person obtaining the consent. Each patient was to receive a copy of the signed ICF.

Background therapy:

None

Evidence for comparator:

Not applicable

Actual start date of recruitment	19 February 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 119
Country: Number of subjects enrolled	Slovakia: 7
Country: Number of subjects enrolled	Bulgaria: 6
Country: Number of subjects enrolled	Czechia: 18
Country: Number of subjects enrolled	Estonia: 3
Country: Number of subjects enrolled	Germany: 16
Country: Number of subjects enrolled	Hungary: 7
Country: Number of subjects enrolled	Italy: 3
Country: Number of subjects enrolled	Belarus: 19
Country: Number of subjects enrolled	Georgia: 16
Country: Number of subjects enrolled	Japan: 22
Country: Number of subjects enrolled	Moldova, Republic of: 17
Country: Number of subjects enrolled	Russian Federation: 14
Country: Number of subjects enrolled	Serbia: 28

Country: Number of subjects enrolled	Korea, Republic of: 11
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	Ukraine: 8
Country: Number of subjects enrolled	United States: 6
Worldwide total number of subjects	322
EEA total number of subjects	179

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	301
From 65 to 84 years	21
85 years and over	0

## Subject disposition

### Recruitment

#### Recruitment details:

This study was conducted in Australia, Belarus, Bulgaria, Czech Republic, Estonia, Georgia, Germany, Hungary, Italy, Japan, Moldova, Poland, Russia, Serbia, Slovakia, South Korea, Taiwan, Ukraine, and the United States of America. A total of 185 sites were activated and 96 sites enrolled subjects. Date of first randomization: 28 Sep 2021.

### Pre-assignment

#### Screening details:

Subjects were eligible if male or female, 18-75 years old at consent (inclusive), had stable vital signs, and had a diagnosis of active mild UC (mMS of 3 or 4) or moderate UC (mMS of 5 to 8). Subjects had to have an endoscopic subscore of  $\geq 2$  and evidence of active UC extending  $\geq 15$  cm from the anal verge, both confirmed by a screening colonoscopy.

### Period 1

Period 1 title	Double-Blind Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

#### Blinding implementation details:

For the Double-Blind Period, the 0.2 mg and 0.4 mg amiselimod capsules and placebo capsules looked identical to maintain the blind. In addition, all white blood cell (WBC) differential values (except total WBC count and absolute neutrophil count) remained blinded throughout the Double-Blind Period. Independent, unblinded, qualified medical professional(s) were responsible for monitoring absolute lymphocyte counts to identify subjects who reached the threshold for discontinuation.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Amiselimod Low Dose Group

#### Arm description:

Subjects initially randomized to the amiselimod low dose group for the Double-Blind Period  
Study Treatment - loading dose: 0.4 mg amiselimod, orally, once daily; maintenance dose: 0.2 mg amiselimod, orally, once daily

Arm type	Experimental
Investigational medicinal product name	Amiselimod
Investigational medicinal product code	MT-1303
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

#### Dosage and administration details:

Loading dose (Days 1-14): Two 0.2 mg amiselimod capsules, orally, once daily  
Maintenance dose (Days 15-85): One 0.2 mg amiselimod capsule, orally, once daily

<b>Arm title</b>	Amiselimod High Dose Group
------------------	----------------------------

#### Arm description:

Subjects initially randomized to the amiselimod high dose group for the Double-Blind Period  
Study Treatment - loading dose: 0.8 mg amiselimod, orally, once daily; maintenance dose: 0.4 mg amiselimod, orally, once daily

Arm type	Experimental
Investigational medicinal product name	Amiselimod
Investigational medicinal product code	MT-1303
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Loading dose (Days 1-14): Two 0.4 mg amiselimod capsules, orally, once daily

Maintenance dose (Days 15-85): One 0.4 mg amiselimod capsule, orally, once daily

<b>Arm title</b>	Placebo Group
Arm description:	
Subjects initially randomized to the placebo group for the Double-Blind Period	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Loading dose (Days 1-14): Two placebo capsules, orally, once daily

Maintenance dose (Days 15-85): One placebo capsule, orally, once daily

<b>Number of subjects in period 1<sup>[1]</sup></b>	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group
Started	107	107	107
Completed	94	96	95
Not completed	13	11	12
Adverse event, serious fatal	-	1	-
Consent withdrawn by subject	5	5	7
Physician decision	-	1	-
Adverse event, non-fatal	5	3	2
Other	3	-	1
Protocol deviation	-	1	2

**Notes:**

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One subject was enrolled but did not receive any study treatment, so this person was not included in the summary tables.

**Period 2**

Period 2 title	Open-label Extension (OLE) Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	OLE Overall Group
Arm description:	
Subjects who completed the Double-Blind Period of the study and who, in the opinion of the Investigator, would benefit from continued treatment, were permitted to participate in the OLE Period. Study Treatment - 0.4 mg amiselimod, orally, once daily	
Arm type	Experimental
Investigational medicinal product name	Amiselimod
Investigational medicinal product code	MT-1303
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
One 0.4 mg amiselimod capsule, orally, once daily	

<b>Number of subjects in period 2<sup>[2]</sup></b>	OLE Overall Group
Started	283
Completed	237
Not completed	46
Physician decision	5
Consent withdrawn by subject	23
Adverse event, non-fatal	9
Other	6
Lost to follow-up	1
Protocol deviation	2

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Two subjects completed the Double-Blind Period but did not enter the OLE Period.

## Baseline characteristics

### Reporting groups

Reporting group title	Amiselimod Low Dose Group
Reporting group description:	
Subjects initially randomized to the amiselimod low dose group for the Double-Blind Period	
Study Treatment - loading dose: 0.4 mg amiselimod, orally, once daily; maintenance dose: 0.2 mg amiselimod, orally, once daily	
Reporting group title	Amiselimod High Dose Group
Reporting group description:	
Subjects initially randomized to the amiselimod high dose group for the Double-Blind Period	
Study Treatment - loading dose: 0.8 mg amiselimod, orally, once daily; maintenance dose: 0.4 mg amiselimod, orally, once daily	
Reporting group title	Placebo Group
Reporting group description:	
Subjects initially randomized to the placebo group for the Double-Blind Period	

Reporting group values	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group
Number of subjects	107	107	107
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	98	101	101
From 65-84 years	9	6	6
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	40.6	41.6	40.5
standard deviation	± 14.46	± 12.42	± 12.43
Gender categorical			
Units: Subjects			
Female	44	43	46
Male	63	64	61
UC Severity			
Units: Subjects			
Mild UC (Modified Mayo Score of 3 or 4)	21	22	22
Moderate UC (Modified Mayo Score of 5 to 8)	86	85	85
History of Corticosteroids			
Units: Subjects			
Yes	92	86	86
No	15	21	21
History of Aminosalicylates			

Units: Subjects			
Yes	102	106	104
No	5	1	3
Previous Exposure to anti-TNF- $\alpha$ agents, anti-integrin, anti-IL, or JAK inhibitors			
Units: Subjects			
Yes	36	31	33
No	71	76	74
Race			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	16	10	9
Black or African American	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	89	97	98
Not Reported	2	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	1	0
Not Hispanic or Latino	104	106	107
Not Reported	3	0	0
Time Since UC Symptom Onset			
Units: Years			
arithmetic mean	8.2227	7.9766	8.0499
standard deviation	$\pm 8.23754$	$\pm 7.79472$	$\pm 6.97550$

<b>Reporting group values</b>	Total		
Number of subjects	321		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	300		
From 65-84 years	21		
85 years and over	0		
Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	133		
Male	188		



UC Severity			
Units: Subjects			
Mild UC (Modified Mayo Score of 3 or 4)	65		
Moderate UC (Modified Mayo Score of 5 to 8)	256		
History of Corticosteroids			
Units: Subjects			
Yes	264		
No	57		
History of Aminosalicylates			
Units: Subjects			
Yes	312		
No	9		
Previous Exposure to anti-TNF- $\alpha$ agents, anti-integrin, anti-IL, or JAK inhibitors			
Units: Subjects			
Yes	100		
No	221		
Race			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	35		
Black or African American	0		
Native Hawaiian or Other Pacific Islander	0		
White	284		
Not Reported	2		
Ethnicity			
Units: Subjects			
Hispanic or Latino	1		
Not Hispanic or Latino	317		
Not Reported	3		
Time Since UC Symptom Onset			
Units: Years			
arithmetic mean			
standard deviation	-		

## End points

### End points reporting groups

Reporting group title	Amiselimod Low Dose Group
Reporting group description: Subjects initially randomized to the amiselimod low dose group for the Double-Blind Period Study Treatment - loading dose: 0.4 mg amiselimod, orally, once daily; maintenance dose: 0.2 mg amiselimod, orally, once daily	
Reporting group title	Amiselimod High Dose Group
Reporting group description: Subjects initially randomized to the amiselimod high dose group for the Double-Blind Period Study Treatment - loading dose: 0.8 mg amiselimod, orally, once daily; maintenance dose: 0.4 mg amiselimod, orally, once daily	
Reporting group title	Placebo Group
Reporting group description: Subjects initially randomized to the placebo group for the Double-Blind Period	
Reporting group title	OLE Overall Group
Reporting group description: Subjects who completed the Double-Blind Period of the study and who, in the opinion of the Investigator, would benefit from continued treatment, were permitted to participate in the OLE Period. Study Treatment - 0.4 mg amiselimod, orally, once daily	
Subject analysis set title	Intent-to-Treat (ITT)
Subject analysis set type	Intention-to-treat
Subject analysis set description: All randomized subjects who received at least 1 dose of study treatment. Subjects in the ITT Population were analyzed according to the study treatment assigned at randomization.	
Subject analysis set title	Safety
Subject analysis set type	Safety analysis
Subject analysis set description: All subjects who received at least one dose of study drug. Subjects in the Safety Population were analyzed according to study drug received. For subjects receiving placebo during the Double-Blind Period, the safety assessments obtained at Day 85 were used for Baseline during the OLE Period.	
Subject analysis set title	OLE Period Safety
Subject analysis set type	Safety analysis
Subject analysis set description: All randomized subjects who received at least 1 dose of study drug and were enrolled in the OLE period of the study. Analysis were according to study drug received.	

### Primary: Change from Baseline in Modified Mayo Score (mMS) at Day 85

End point title	Change from Baseline in Modified Mayo Score (mMS) at Day 85
End point description: The mMS consisted of the endoscopic (excluding friability), rectal bleeding, and stool frequency subscores. Change from baseline was calculated as Day 85 value — Baseline value. Subjects who discontinued prematurely for any reason and for whom a post-Baseline Mayo endoscopic subscore was not available at the Day 85/End of Treatment (EOT) Visit had the Baseline endoscopic categorization carried forward for purposes of this endpoint. For subjects who did not record diary data on stool frequency and rectal bleeding through Day 85/EOT, the value from the last available visit was to be carried forward for a last observation carried forward (LOCF) analysis of the primary endpoint. This endpoint was analyzed in the ITT Population.	
End point type	Primary
End point timeframe: Baseline to Day 85	

<b>End point values</b>	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	107	107	107	
Units: Change in mMS				
arithmetic mean (standard deviation)	-2.3 ( $\pm$ 2.18)	-2.3 ( $\pm$ 2.21)	-1.6 ( $\pm$ 2.17)	

## Statistical analyses

<b>Statistical analysis title</b>	Amiselimod Low Dose Vs Placebo
Comparison groups	Amiselimod Low Dose Group v Placebo Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.01 <sup>[1]</sup>
Method	ANCOVA
Parameter estimate	Least Squares Means Difference
Point estimate	-0.74
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.21
upper limit	-0.27

Notes:

[1] - P-value was generated from an analysis of covariance (ANCOVA) model which included treatment, severity (mild or moderate UC), concurrent corticosteroid use (Y/N), and Baseline value as covariates.

<b>Statistical analysis title</b>	Amiselimod High Dose Vs Placebo
Comparison groups	Placebo Group v Amiselimod High Dose Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.008 <sup>[2]</sup>
Method	ANCOVA
Parameter estimate	Least Squares Means Difference
Point estimate	-0.76
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.23
upper limit	-0.29

Notes:

[2] - P-value was generated from an ANCOVA model which included treatment, severity (mild or moderate UC), concurrent corticosteroid use (Y/N), and Baseline value as covariates.

## Secondary: Proportion of Subjects with Endoscopic Improvement at Day 85

End point title	Proportion of Subjects with Endoscopic Improvement at Day 85
End point description:	
Endoscopic improvement was defined as a Mayo endoscopic subscore of $\leq 1$ . Endoscopic improvement subjects who discontinued prematurely for any reason and for whom a Mayo endoscopic subscore was not available at the Day 85 visit were categorized as Non-Responders for purposes of the endpoint. This endpoint was analyzed in the ITT Population.	
End point type	Secondary
End point timeframe:	
Baseline to Day 85	

End point values	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	107 <sup>[3]</sup>	107 <sup>[4]</sup>	107 <sup>[5]</sup>	
Units: Subjects with endoscopic improvement	44	46	25	

Notes:

[3] - Percentage with endoscopic improvement: 41.1%

[4] - Percentage with endoscopic improvement: 43.0%

[5] - Percentage with endoscopic improvement: 23.4%

## Statistical analyses

<b>Statistical analysis title</b>	Amiselimod Low Dose vs Placebo
Comparison groups	Placebo Group v Amiselimod Low Dose Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.007 <sup>[6]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.174
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.068
upper limit	0.28

Notes:

[6] - P-value was generated by stratified Cochran-Mantel-Haenszel (CMH) test stratified by severity (mild UC or moderate UC) and concurrent corticosteroid use (Y/N).

<b>Statistical analysis title</b>	Amiselimod High Dose vs Placebo
Comparison groups	Placebo Group v Amiselimod High Dose Group

Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003 <sup>[7]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.194
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.091
upper limit	0.298

Notes:

[7] - P-value was generated by stratified CMH test stratified by severity (mild UC or moderate UC) and concurrent corticosteroid use (Y/N).

## Secondary: Change from Baseline in 2-Component Mayo Score at Day 85

End point title	Change from Baseline in 2-Component Mayo Score at Day 85
-----------------	--

End point description:

The 2-component Mayo Score consisted of the endoscopic and rectal bleeding subscores. Change from baseline was calculated as Day 85 value – Baseline value. For subjects who did not record diary data on rectal bleeding through Day 85/EOT, the last recorded value in the diary was carried forward for an LOCF analysis of the primary endpoint. This endpoint was analyzed in the ITT Population.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 85

End point values	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	107	107	107	
Units: Change in 2-component Mayo Score				
arithmetic mean (standard deviation)	-1.6 (± 1.58)	-1.6 (± 1.61)	-1.0 (± 1.51)	

## Statistical analyses

<b>Statistical analysis title</b>	Amiselimod Low Dose Vs Placebo
Comparison groups	Amiselimod Low Dose Group v Placebo Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003 <sup>[8]</sup>
Method	ANCOVA
Parameter estimate	Least Squares Means Difference
Point estimate	-0.61

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.94
upper limit	-0.28

Notes:

[8] - P-value was generated from an ANCOVA model which included treatment, severity (mild or moderate UC), concurrent corticosteroid use (Y/N), prior aminosalicylates use (Y/N), and Baseline value as covariates.

<b>Statistical analysis title</b>	Amiselimod High Dose Vs Placebo
Comparison groups	Placebo Group v Amiselimod High Dose Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002 <sup>[9]</sup>
Method	ANCOVA
Parameter estimate	Least Squares Means Difference
Point estimate	-0.61
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.94
upper limit	-0.28

Notes:

[9] - P-value was generated from an ANCOVA model which included treatment, severity (mild or moderate UC), concurrent corticosteroid use (Y/N), prior aminosalicylates use (Y/N), and Baseline value as covariates.

### **Secondary: Proportion of Subjects with Clinical Remission at Day 85 Based on the mMS with the April 2022 United States Food and Drug Administration (FDA) New UC Guideline Definition**

End point title	Proportion of Subjects with Clinical Remission at Day 85 Based on the mMS with the April 2022 United States Food and Drug Administration (FDA) New UC Guideline Definition
-----------------	--

End point description:

Clinical remission based on the FDA 2022 UC (draft) guidance was defined as follows: endoscopy subscore of  $\leq 1$  (excludes friability) + rectal bleeding subscore of 0 + stool frequency subscore of  $\leq 1$ . This endpoint was analyzed in the ITT Population.

End point type	Secondary
End point timeframe:	
Baseline to Day 85	

End point values	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	107 <sup>[10]</sup>	107 <sup>[11]</sup>	107 <sup>[12]</sup>	
Units: Subjects with clinical remission	35	33	19	

Notes:

[10] - Percentage with clinical remission: 32.7%

[11] - Percentage with clinical remission: 30.8%

[12] - Percentage with clinical remission: 17.8%

### Statistical analyses

<b>Statistical analysis title</b>	Amiselimod Low Dose vs Placebo
Comparison groups	Amiselimod Low Dose Group v Placebo Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.015 <sup>[13]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.146
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.048
upper limit	0.245

Notes:

[13] - P-value was generated by stratified CMH test stratified by severity (mild UC or moderate UC) and concurrent corticosteroid use (Y/N).

<b>Statistical analysis title</b>	Amiselimod High Dose vs Placebo
Comparison groups	Placebo Group v Amiselimod High Dose Group
Number of subjects included in analysis	214
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.029 <sup>[14]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Proportion
Point estimate	0.129
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.033
upper limit	0.224

Notes:

[14] - P-value was generated by stratified CMH test stratified by severity (mild UC or moderate UC) and concurrent corticosteroid use (Y/N).

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events and serious adverse events (SAEs) were to be recorded from the signing of the informed consent through the End of Study Visit or 84 days after the last dose of investigation product (IP).

Adverse event reporting additional description:

Double-Blind Period (up to 12 weeks of treatment): Results reported for the amiselimod low dose, amiselimod high dose, and placebo groups in the Safety Population.

OLE Period (up to 36 additional weeks of treatment): Results reported for the OLE overall group in the OLE Safety Population.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	23.1

### Reporting groups

Reporting group title	Amiselimod Low Dose Group
-----------------------	---------------------------

Reporting group description:

Subjects initially randomized to the amiselimod low dose group for the Double-Blind Period  
Study Treatment - loading dose: 0.4 mg amiselimod, orally, once daily; maintenance dose: 0.2 mg amiselimod, orally, once daily

Reporting group title	Amiselimod High Dose Group
-----------------------	----------------------------

Reporting group description:

Subjects initially randomized to the amiselimod high dose for the Double-Blind Period  
Study Treatment - loading dose: 0.8 mg amiselimod, orally, once daily; maintenance dose: 0.4 mg amiselimod, orally, once daily

Reporting group title	Placebo Group
-----------------------	---------------

Reporting group description:

Subjects initially randomized to the placebo group for the Double-Blind Period

Reporting group title	OLE Overall Group
-----------------------	-------------------

Reporting group description:

Subjects who completed the Double-Blind Period of the study and who, in the opinion of the Investigator, would benefit from continued treatment, were permitted to participate in the OLE Period.  
Study Treatment - 0.4 mg amiselimod, orally, once daily

Serious adverse events	Amiselimod Low Dose Group	Amiselimod High Dose Group	Placebo Group
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 107 (1.87%)	3 / 107 (2.80%)	1 / 107 (0.93%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Pancreatic carcinoma	Additional description: The pancreatic carcinoma in the OLE overall group was assessed by the Investigator as related to study treatment, but the Sponsor determined it was unrelated to treatment due to the presence of an abnormal pancreatic lesion prior to active treatment.		



subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	2 / 107 (1.87%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic gastritis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Ovarian cyst ruptured			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Gallbladder polyp			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Completed suicide			

subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Osteonecrosis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Campylobacter colitis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complicated appendicitis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster oticus			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative abscess			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	OLE Overall Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 283 (5.65%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Pancreatic carcinoma	Additional description: The pancreatic carcinoma in the OLE overall group was assessed by the Investigator as related to study treatment, but the Sponsor determined it was unrelated to treatment due to the presence of an abnormal pancreatic lesion prior to active treatment.		
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Uterine leiomyoma			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	6 / 283 (2.12%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Chronic gastritis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Ovarian cyst ruptured			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Hepatobiliary disorders			
Gallbladder polyp			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteonecrosis			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal osteoarthritis			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Campylobacter colitis			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Complicated appendicitis			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Herpes zoster			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Herpes zoster oticus			

subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Postoperative abscess			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0.5 %

<b>Non-serious adverse events</b>	<b>Amiselimod Low Dose Group</b>	<b>Amiselimod High Dose Group</b>	<b>Placebo Group</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	49 / 107 (45.79%)	59 / 107 (55.14%)	44 / 107 (41.12%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colorectal adenoma			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	3 / 107 (2.80%)	4 / 107 (3.74%)	3 / 107 (2.80%)
occurrences (all)	3	4	3
Thrombophlebitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Surgical and medical procedures			
Abortion induced			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	2 / 107 (1.87%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	2	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences (all)	0	1	1

Asthenia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Feeling cold			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Neck pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	2
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Genital haemorrhage			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Epistaxis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	1	0	1
Apnoea			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Nasal ulcer			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1

Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences (all)	0	1	1
Anxiety			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Depressed mood			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Nervousness			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Neurosis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Investigations			
Lymphocyte count decreased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 107 (0.93%)	2 / 107 (1.87%)	0 / 107 (0.00%)
occurrences (all)	1	2	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Blood calcium decreased			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Blood glucose increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	1	0	1
Blood potassium increased			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Transaminases increased			

subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences (all)	0	1	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Blood magnesium decreased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
International normalised ratio increased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Clostridium test positive			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Foot fracture			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Rib fracture			



subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Ventricular tachycardia			
subjects affected / exposed	2 / 107 (1.87%)	4 / 107 (3.74%)	0 / 107 (0.00%)
occurrences (all)	2	4	0
Tachycardia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	2 / 107 (1.87%)
occurrences (all)	0	1	2
Sinus bradycardia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Atrioventricular block second degree			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Bradycardia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Bundle branch block left			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Palpitations			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Cardiomyopathy			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			

subjects affected / exposed	5 / 107 (4.67%)	2 / 107 (1.87%)	1 / 107 (0.93%)
occurrences (all)	5	2	1
Paraesthesia			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Dizziness			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Dysgraphia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	2	0
Lumbar radiculopathy			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Restless legs syndrome			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Sciatica			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Migraine			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	8 / 107 (7.48%)	17 / 107 (15.89%)	0 / 107 (0.00%)
occurrences (all)	8	21	0
Anaemia			
subjects affected / exposed	6 / 107 (5.61%)	4 / 107 (3.74%)	4 / 107 (3.74%)
occurrences (all)	6	5	4

Neutropenia			
subjects affected / exposed	2 / 107 (1.87%)	6 / 107 (5.61%)	0 / 107 (0.00%)
occurrences (all)	2	7	0
Lymphopenia			
subjects affected / exposed	0 / 107 (0.00%)	2 / 107 (1.87%)	0 / 107 (0.00%)
occurrences (all)	0	2	0
Thrombocytopenia			
subjects affected / exposed	2 / 107 (1.87%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	2	0	0
Eosinophilia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Macular fibrosis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Retinal degeneration			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			

Colitis ulcerative			
subjects affected / exposed	6 / 107 (5.61%)	2 / 107 (1.87%)	3 / 107 (2.80%)
occurrences (all)	6	2	3
Abdominal pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	4 / 107 (3.74%)
occurrences (all)	1	0	5
Food poisoning			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	3 / 107 (2.80%)
occurrences (all)	0	0	3
Large intestine polyp			
subjects affected / exposed	1 / 107 (0.93%)	2 / 107 (1.87%)	1 / 107 (0.93%)
occurrences (all)	1	2	1
Diarrhoea			
subjects affected / exposed	2 / 107 (1.87%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	2	0	1
Nausea			
subjects affected / exposed	2 / 107 (1.87%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	2	0	1
Vomiting			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	2 / 107 (1.87%)
occurrences (all)	0	1	2
Aphthous ulcer			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences (all)	0	1	1
Dyspepsia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	1	0	1
Enteritis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	1	0	1
Colitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Dental dysaesthesia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0

Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Faeces hard			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Gingival swelling			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Haematochezia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	2	0	0
Haemorrhoids			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Ileal ulcer			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Large intestinal ulcer			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Rectal haemorrhage			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Abdominal pain lower			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0

Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Hyperbilirubinaemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Hypertransaminasaemia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 107 (0.00%)	3 / 107 (2.80%)	1 / 107 (0.93%)
occurrences (all)	0	3	1
Acne			
subjects affected / exposed	1 / 107 (0.93%)	2 / 107 (1.87%)	0 / 107 (0.00%)
occurrences (all)	1	2	0
Dermatitis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	1	0	1
Dermatitis atopic			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences (all)	0	1	1
Cold sweat			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Ecchymosis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Hyperhidrosis			

subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Pigmentation disorder			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Scar pain			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Nephrolithiasis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Renal cyst			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Renal colic			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 107 (1.87%)	1 / 107 (0.93%)	2 / 107 (1.87%)
occurrences (all)	2	1	3
Back pain			

subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	5	0	0
Muscular weakness			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Osteonecrosis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Sacral pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	4 / 107 (3.74%)	5 / 107 (4.67%)	6 / 107 (5.61%)
occurrences (all)	4	5	6
Nasopharyngitis			
subjects affected / exposed	3 / 107 (2.80%)	1 / 107 (0.93%)	4 / 107 (3.74%)
occurrences (all)	3	1	4



Upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 107 (2.80%) 3	1 / 107 (0.93%) 1	2 / 107 (1.87%) 3
Influenza subjects affected / exposed occurrences (all)	2 / 107 (1.87%) 2	3 / 107 (2.80%) 3	1 / 107 (0.93%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	1 / 107 (0.93%) 1	1 / 107 (0.93%) 1
Bronchitis subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	1 / 107 (0.93%) 1	0 / 107 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 2	1 / 107 (0.93%) 1	0 / 107 (0.00%) 0
Bacteriuria subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	0 / 107 (0.00%) 0	1 / 107 (0.93%) 1
Campylobacter infection subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 107 (0.00%) 0	0 / 107 (0.00%) 0
Clostridium difficile infection subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	0 / 107 (0.00%) 0	1 / 107 (0.93%) 1
Escherichia infection subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 107 (0.00%) 0	0 / 107 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	1 / 107 (0.93%) 1	0 / 107 (0.00%) 0
Mastitis subjects affected / exposed occurrences (all)	0 / 107 (0.00%) 0	0 / 107 (0.00%) 0	1 / 107 (0.93%) 1
Oral herpes subjects affected / exposed occurrences (all)	1 / 107 (0.93%) 1	0 / 107 (0.00%) 0	0 / 107 (0.00%) 0

Paronychia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Pulpitis dental			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Salmonellosis			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	1 / 107 (0.93%)
occurrences (all)	0	1	1
Iron deficiency			
subjects affected / exposed	1 / 107 (0.93%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	1	1	0
Glucose tolerance impaired			

subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Hypernatraemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Hypocalcaemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Hypochloraemia			
subjects affected / exposed	1 / 107 (0.93%)	0 / 107 (0.00%)	0 / 107 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 107 (0.00%)	1 / 107 (0.93%)	0 / 107 (0.00%)
occurrences (all)	0	1	0
Vitamin D deficiency			
subjects affected / exposed	0 / 107 (0.00%)	0 / 107 (0.00%)	1 / 107 (0.93%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	OLE Overall Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	202 / 283 (71.38%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colorectal adenoma			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	4		
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	6 / 283 (2.12%) 6		
Thrombophlebitis subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Surgical and medical procedures Abortion induced subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	7 / 283 (2.47%) 7		
Non-cardiac chest pain subjects affected / exposed occurrences (all)	1 / 283 (0.35%) 1		
Asthenia subjects affected / exposed occurrences (all)	1 / 283 (0.35%) 1		
Chest pain subjects affected / exposed occurrences (all)	1 / 283 (0.35%) 1		
Feeling cold subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Influenza like illness subjects affected / exposed occurrences (all)	3 / 283 (1.06%) 3		
Neck pain subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	1 / 283 (0.35%) 1		

Reproductive system and breast disorders			
Genital haemorrhage			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 283 (1.41%)		
occurrences (all)	5		
Epistaxis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Apnoea			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Nasal ulcer			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Depressed mood			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Nervousness			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Neurosis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Investigations			
Lymphocyte count decreased			

subjects affected / exposed	14 / 283 (4.95%)		
occurrences (all)	19		
Alanine aminotransferase increased			
subjects affected / exposed	7 / 283 (2.47%)		
occurrences (all)	7		
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 283 (1.41%)		
occurrences (all)	4		
Blood calcium decreased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Blood glucose increased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Blood potassium increased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Transaminases increased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Activated partial thromboplastin time prolonged			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Blood magnesium decreased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
International normalised ratio increased			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Neutrophil count increased			

subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
White blood cell count decreased subjects affected / exposed occurrences (all)	5 / 283 (1.77%) 9		
Clostridium test positive subjects affected / exposed occurrences (all)	2 / 283 (0.71%) 2		
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	2 / 283 (0.71%) 2		
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	1 / 283 (0.35%) 1		
Foot fracture subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Rib fracture subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Skin abrasion subjects affected / exposed occurrences (all)	2 / 283 (0.71%) 2		
Cardiac disorders			
Ventricular tachycardia subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Tachycardia subjects affected / exposed occurrences (all)	0 / 283 (0.00%) 0		
Sinus bradycardia subjects affected / exposed occurrences (all)	2 / 283 (0.71%) 2		
Atrioventricular block second degree			

subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Bradycardia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Bundle branch block left			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Palpitations			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Cardiomyopathy			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Ventricular extrasystoles			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	3		
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 283 (1.41%)		
occurrences (all)	4		
Paraesthesia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Dysgraphia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypoaesthesia			
subjects affected / exposed	3 / 283 (1.06%)		
occurrences (all)	3		
Lumbar radiculopathy			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		



Restless legs syndrome			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Migraine			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	44 / 283 (15.55%)		
occurrences (all)	51		
Anaemia			
subjects affected / exposed	10 / 283 (3.53%)		
occurrences (all)	11		
Neutropenia			
subjects affected / exposed	12 / 283 (4.24%)		
occurrences (all)	15		
Lymphopenia			
subjects affected / exposed	80 / 283 (28.27%)		
occurrences (all)	90		
Thrombocytopenia			
subjects affected / exposed	3 / 283 (1.06%)		
occurrences (all)	3		
Eosinophilia			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Iron deficiency anaemia			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Eye disorders			

Cataract			
subjects affected / exposed	4 / 283 (1.41%)		
occurrences (all)	5		
Dry eye			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Macular fibrosis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Retinal degeneration			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Visual acuity reduced			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Visual impairment			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	27 / 283 (9.54%)		
occurrences (all)	30		
Abdominal pain			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Food poisoning			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Large intestine polyp			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	4 / 283 (1.41%)		
occurrences (all)	4		
Nausea			

subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Aphthous ulcer			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Enteritis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Colitis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Dental dysaesthesia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Eructation			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Faeces hard			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorder			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Gingival swelling			

subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Haematochezia			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	3 / 283 (1.06%)		
occurrences (all)	3		
Ileal ulcer			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Large intestinal ulcer			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Rectal haemorrhage			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Abdominal pain lower			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Hyperbilirubinaemia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypertransaminasaemia			
subjects affected / exposed	3 / 283 (1.06%)		
occurrences (all)	3		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Acne			

subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Dermatitis</b>			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Dermatitis atopic</b>			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Rash</b>			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
<b>Cold sweat</b>			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Ecchymosis</b>			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Eczema</b>			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
<b>Hyperhidrosis</b>			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
<b>Pigmentation disorder</b>			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Pruritus</b>			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
<b>Scar pain</b>			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
<b>Erythema</b>			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
<b>Renal and urinary disorders</b>			

Calculus urinary			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Haematuria			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Nephrolithiasis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Renal cyst			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Renal colic			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	12 / 283 (4.24%)		
occurrences (all)	12		
Back pain			
subjects affected / exposed	3 / 283 (1.06%)		
occurrences (all)	3		
Muscle spasms			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Musculoskeletal stiffness			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Osteonecrosis			

subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Sacral pain			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Spinal pain			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Infections and infestations			
COVID-19			
subjects affected / exposed	11 / 283 (3.89%)		
occurrences (all)	11		
Nasopharyngitis			
subjects affected / exposed	10 / 283 (3.53%)		
occurrences (all)	10		
Upper respiratory tract infection			
subjects affected / exposed	7 / 283 (2.47%)		
occurrences (all)	9		
Influenza			
subjects affected / exposed	6 / 283 (2.12%)		
occurrences (all)	7		
Urinary tract infection			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	2		
Bronchitis			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Gastroenteritis			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		

Bacteriuria			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Campylobacter infection			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Clostridium difficile infection			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Escherichia infection			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Lower respiratory tract infection			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Mastitis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Paronychia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Pulpitis dental			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Rhinitis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Salmonellosis			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Urinary tract infection bacterial			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		



Viral infection			
subjects affected / exposed	3 / 283 (1.06%)		
occurrences (all)	4		
Conjunctivitis			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Pharyngitis			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Tonsillitis			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Iron deficiency			
subjects affected / exposed	2 / 283 (0.71%)		
occurrences (all)	2		
Glucose tolerance impaired			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		
Hyperglycaemia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypernatraemia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypertriglyceridaemia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypochloraemia			

subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 283 (0.00%)		
occurrences (all)	0		
Vitamin D deficiency			
subjects affected / exposed	1 / 283 (0.35%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 September 2020	<ul style="list-style-type: none"><li>•Changes made throughout the protocol related to addition of the OLE Period</li><li>•Updates made to clarify inclusion criterion (IC) #3 (revised) and #4 (added) regarding endoscopic subscore</li><li>•Clarification of exclusion criterion (EC) #36 for prior treatment with Sphingosine 1-Phosphates</li><li>•Changed EC #16 to allow re-screening 7 days after treatment for C. difficile rather than 60 days</li><li>•Text added to clarify period for hypothesis testing to be conducted after all subjects completed the Double-Blind Period</li><li>•Clarification of EC #4 to state "history or evidence of any colonic resection or subtotal colectomy within 1 year prior to randomization"</li><li>•Clarification of EC #26 to state "History or evidence of two or more failures with biologic treatment for UC (primary non-responders)"</li><li>•For EC #28 and #29, clarified that immunosuppressants were not allowed within 28 days prior to randomization rather than 28 days prior to screening</li><li>•Criteria for discontinuation modified to allow adequate time to collect second absolute lymphocyte count value, and alanine aminotransferase and/or aspartate aminotransferase value</li><li>•Clarification that the 24-hour electrocardiograms (ECGs) were to begin within 1 hour prior to IP dose and to change the 24-hour ECGs to be collected for all subjects</li><li>•Schedule for collection of colonoscopy adjusted to allow more time for collection (14 to 28 days prior to Baseline Visit)</li><li>•Section added to include major adverse cardiac events (MACE) as an adverse event of special interest; text added to describe methods for the analysis of MACE</li></ul>
03 December 2020	<ul style="list-style-type: none"><li>•Clarified dosing: changed from "Group A (low dose): 0.4 mg amiselimod capsule + placebo" to "Group A (low dose): Two 0.2 mg amiselimod capsules, orally, QD"</li><li>•Background section updated to match Investigator's Brochure</li><li>•History of tuberculosis deleted from EC #11</li><li>•History of hepatitis B virus (HBV) and hepatitis C virus (HCV) deleted and results of HBV and HCV updated in EC #12</li><li>•Requirements for progressive multifocal leukoencephalopathy (PML) EC #14 updated</li><li>•Clarified EC #16 for previous or current C. difficile diagnoses; EC #47 updated to reflect change in C. difficile EC #16</li><li>•Updated requirement for stable dose of concomitant medications to within 28 days prior to randomization</li><li>•New EC #45 added for diffusing capacity of the lungs for carbon monoxide (DLCO) assessment</li><li>•Clarified requirements for Daily Symptoms Diary</li><li>•Changed definition of laboratory results that were to be blinded/unblinded during the study; clarified that laboratory values are not blinded during the OLE Period</li><li>•Added text on the DLCO assessment</li><li>•Clarified use of combined subjective and objective PML checklist; instructions added on restarting IP in the case of a positive finding on the PML checklist</li><li>•Clarified that urine alcohol and urine cotinine were not part of urine drug screen; urine drug screen was removed from Baseline Visit and added to Screening Visit; and added DLCO to pulmonary function tests (PFTs)</li><li>•C-reactive protein was added to Day 421 visit</li><li>•Prohibited use of drugs that prolong QT interval</li><li>•Weight measurement added to Day 169 visit</li><li>•Clarified how "normal" stool frequency was to be collected for scoring of Mayo stool frequency subscore</li><li>•Added requirement to collect pharmacokinetics sample for a cardiac-related SAE</li><li>•Clarified the recording of both local and central Mayo endoscopy subscores and determination of histological scoring at central laboratory</li><li>•Clarified the timing of performing EuroQol 5-Dimension 3-Level and Patient Global Impression of Change surveys</li></ul>

03 March 2022	<ul style="list-style-type: none"> <li>•Revised number of subjects from 175 to 189 and removed Africa</li> <li>•Revised Screening Period from up to 4 weeks to up to 35 days</li> <li>•Added a visit window for subjects that did not participate in the OLE Period; subjects were to be followed for 84 (<math>\pm 10</math>) days in a Safety Follow-Up Period</li> <li>•Revised IC #2 to state subjects were eligible if they had "stable vital signs" rather than "normal vital signs"; changed IC ranges for heart rate (50-100 bpm), systolic blood pressure (<math>&gt;90</math> and <math>&lt;160</math> mmHg), and diastolic blood pressure (<math>&gt;50</math> and <math>&lt;100</math> mmHg)</li> <li>•Revised references to prednisolone dosing to "<math>\leq 20</math> mg prednisolone equivalent per day;" clarified that tapering of prednisolone was allowed during the OLE period</li> <li>•Revised EC #12 from "previous shingles outbreak" to "history of disseminated herpes zoster"</li> <li>•Corrected the common standard deviation used in the sample size determination from 2.2 to 3.0</li> <li>•Added details of a planned interim analysis</li> <li>•Clarified IC #7 regarding pregnancy testing to include "a urine pregnancy test at each subsequent study visit, and additionally at monthly intervals as applicable"</li> <li>•Corrected EC #11 regarding timing for any prior X-ray done in the 12 weeks prior to "Day 1" rather than "screening"</li> <li>•Revised EC #35 to specify non-oral (intravenous [IV] or rectal) corticosteroid use ("IV corticosteroid within 4 weeks of the Screening Visit; rectal corticosteroid within 2 weeks of the Screening Visit")</li> <li>•Revised EC #40 to change the definition of low heart rate from "<math>&lt;55</math>" to "<math>&lt;50</math>"</li> <li>•Section added to allow and specify restrictions around re-screening</li> <li>•Revised timing of PFT testing in relation to the Baseline Visit (Day 1)</li> <li>•Clarified the timing for collection of stool sample and to loosen the associated restrictions</li> <li>•Revised timing of colonoscopy with colonic mucosal biopsy to allow for randomization of subjects in <math>&lt;14</math> days if the colonoscopy results were available sooner</li> <li>•Clarified that IP was to be dispensed at the Day 29 and Day 57 Visits</li> </ul>
---------------	---

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported